Physician profile
Robert Belkin
NPI 1487657698
$1,057.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2022: $12.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $314.19 | 2019 | |
| Boston Scientific Corporation | $241.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $166.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.78 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $74.93 | 2019 | |
| Amgen INC. | $37.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.80 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.69 | 2019 | |
| Abbott Laboratories | $24.21 | 2019 | |
| Portola Pharmaceuticals, LLC | $23.77 | 2019 | |
| Pfizer INC. | $17.36 | 2019 | |
| Abbvie INC. | $12.60 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Belkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.